Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- June 7, 2022 Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
- June 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- June 1, 2022 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- June 1, 2022 Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy
- May 12, 2022 Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
- May 6, 2022 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 5, 2022 Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
- May 4, 2022 Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
- May 3, 2022 Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
- May 2, 2022 Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Displaying 91 - 100 of 279